Company BiomX Inc. Nyse

Equities

PHGE.U

US09090D2027

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Nyse Other stock markets 21:15:01 05/07/2024 BST			5-day change	1st Jan Change
0.4 ^USD	0.00%		0.00%	+58.73%

05-21	Transcript : BiomX Inc., Q1 2024 Earnings Call, May 21, 2024
05-20	BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Number of employees: 65

Managers	Title	Age	Since
Jonathan Solomon CEO	Chief Executive Officer	47	27/10/19
Anat Primovich IRC	Investor Relations Contact	-	30/09/21
Inbal Benjamini-Elran HRO	Human Resources Officer	-	31/12/19
Myriam Golembo PRN	Corporate Officer/Principal	59	30/10/19
Merav Bassan PRN	Corporate Officer/Principal	59	27/10/19
Assaf Oron PRN	Corporate Officer/Principal	49	27/10/19

Members of the board	Title	Age	Since
Russell Greig CHM	Chairman	71	27/10/19
Jonathan Solomon CEO	Chief Executive Officer	47	27/10/19
Edward Williams BRD	Director/Board Member	68	11/10/23
Alan Moses BRD	Director/Board Member	76	01/10/20

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	69,806,440	51,077,818 ( 73.17 %)	0	73.17 %
Stock B	0	256,887	0	0

Name	Equities	%	Valuation
OrbiMed Advisors Private Equity 19.73 %	13,773,653	19.73 %	5 M $
Cystic Fibrosis Foundation 13.37 %	9,330,580	13.37 %	3 M $
Nimble Partners LLC 7.309 %	5,102,041	7.309 %	2 M $
AMR Action Fund GP LLC 4.376 %	3,054,870	4.376 %	1 M $
Rodney Hodges 4.068 %	2,839,714	4.068 %	954 144 $
Johnson & Johnson Innovation - JJDC, Inc. 2.755 %	1,923,201	2.755 %	646 196 $
Eight Enterprises LLC 1.556 %	1,086,191	1.556 %	364 960 $
Chidozie Ugwumba 1.322 %	922,800	1.322 %	310 061 $
JSR CORPORATION 0.3581 %	250,000	0.3581 %	84 000 $
Renaissance Technologies LLC 0.1155 %	80,600	0.1155 %	27 082 $

Name	Equities	%	Valuation
Walleye Capital LLC 0.0276 %	12,688	0.0276 %	4 745 $
Goldman Sachs & Co. LLC 0.0226 %	10,392	0.0226 %	3 887 $
UBS Securities LLC 0.000091 %	42	0.000091 %	16 $

BiomX, Inc.

22 Einstein Street Floor 4

7414003, Ness Ziona

http://www.biomx.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.3465 USD

Average target price

2.167 USD

Spread / Average Target

+525.30%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+18.45%	122B
REGENERON PHARMACEUTICALS, INC.	+19.57%	112B
BIONTECH SE	-23.91%	19.33B
GENMAB A/S	-18.45%	16.17B
BEIGENE, LTD.	-18.75%	15.6B
WUXI APPTEC CO., LTD.	-49.33%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+7.13%	14B
INSMED INCORPORATED	+126.49%	11.29B

Bio Therapeutic Drugs